Filtros de búsqueda

Lista de obras de Jacopo Giuliani

A path for diagnosis and therapy of colon cancer: a continuous quality improvement

artículo científico publicado en 2014

A severe delayed infusion reaction induced by trastuzumab: a life-threatening condition ⬇️

artículo científico publicado el 7 de julio de 2012

Acute Liver Failure Caused by Metastatic Breast Cancer: Can We Expect Some Results from Chemotherapy?

artículo científico publicado en 2015

Ampulla of Vater carcinoma in real-world clinical practice: a case series.

artículo científico publicado en 2015

Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs

artículo científico publicado en 2018

COVID-19 and Cancer: A Clear Change Not Only in Daily Clinical Practice But Also in Clinical Research Management

scientific article published on 20 November 2020

Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic

artículo científico publicado en 2020

Cancer relating symptoms in homecare cancer patients: which impact in daily clinical practice?

artículo científico publicado en 2013

Carboplatin-containing regimens as front-line treatment for advanced non-small-cell lung cancer in two groups of elderly.

artículo científico publicado en 2013

Case Report of a Well-Differentiated Papillary Mesothelioma of the Tunica Vaginalis in an Undescended Testis With Review of Literature.

artículo científico publicado en 2016

Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers

artículo científico publicado en 2018

Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question

scientific article published on 25 February 2015

Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report

scientific article published on 29 November 2018

Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma

scientific article published on 22 November 2018

Cost-effectiveness of first-line hormone-therapies in chemonaïve castration-resistant prostate cancer Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs.

artículo científico publicado en 2017

Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life

scientific article published on 10 June 2019

Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice

artículo científico publicado en 2017

Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs

artículo científico publicado en 2017

FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer

scientific article published on 19 January 2019

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

scientific article published on 01 July 2019

First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs

scientific article published on 08 September 2018

Gastrointestinal stromal tumors and other malignancies: a case series.

artículo científico

Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate

artículo científico publicado en 2013

Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level

scientific article published on 17 August 2019

Immunotherapy and Targeted Therapies in Metastatic Renal Cell Carcinoma: Is There a Preferred Sequence? ⬇️

artículo científico publicado el 27 de junio de 2012

Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice?

artículo científico publicado en 2019

Intraperitoneal Hyperthermic Chemotherapy: Which Drugs? ⬇️

artículo científico publicado el 1 de marzo de 2014

Intravenous midline catheter usage: which clinical impact in homecare patients?

artículo científico publicado en 2013

Is there a real need of adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma?

artículo científico publicado en 2014

La combinazione di gemcitabina e oxaliplatino (GEMOX) nel trattamento del carcinoma pancreatico in fase avanzata di malattia: le notizie sulla mia morte sono state esagerate?

artículo científico publicado en 2017

Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients

artículo científico publicado en 2015

Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'

scientific article published on 30 October 2019

Liver metastases from primary rectal cancer: a multidisciplinary reverse approach.

artículo científico publicado en 2013

Long-term survival in advanced pancreatic cancer

artículo científico publicado en 2018

Management of advanced pancreatic cancer in daily clinical practice.

artículo científico publicado en 2015

Multidisciplinary Approach as the Key Factor in the Management of Liver Metastases from Colorectal Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2013

Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment

scientific article published on 04 August 2019

Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.

artículo científico publicado en 2018

Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs

artículo científico publicado en 2017

Off-label prescription of anti-cancer drugs in Italy: what responsibilities?

artículo científico publicado en 2013

Oncological quality indicators and Colorectal Cancer Program: data from 2009-2010 of University Hospital in Ferrara, Italy

artículo científico publicado el 1 de febrero de 2012

P-050The pharmacological costs of first-line therapies in unselected advanced colorectal cancer patients: a review of published phase III trials.

artículo científico publicado en 2016

Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs

artículo científico publicado en 2019

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials

artículo científico publicado en 2015

Platinum antitumor complexes

artículo científico publicado en 2015

Primary Malignant Fibrous Histiocytoma of Vater’s Papilla: First Reported Case ⬇️

artículo científico publicado el 1 de septiembre de 2013

Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.

artículo científico publicado en 2015

Radically resected pancreatic cancer and adjuvant treatment. A review of the literature

artículo científico publicado en 2013

Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041: Second-line Treatment in Metastatic Renal Cell Carcinoma. Can

scientific article published on 31 October 2017

Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs

scientific article published on 23 February 2018

Second-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?

artículo científico publicado en 2013

Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor? ⬇️

artículo científico publicado el 28 de marzo de 2013

Spinal tuberculosis simulating metastatic malignancy: an unusual condition

artículo científico publicado en 2014

Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer

artículo científico publicado en 2014

The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab

scientific article published on 01 July 2019

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating e

artículo científico publicado en 2016

The Multidisciplinary Management of Cancer in Daily Clinical Practice: Towards a Community Hospital Comprehensive Cancer Center.

artículo científico publicado en 2016

The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies

artículo científico

The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil

artículo científico publicado en 2019

The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-Inhibitors.

artículo científico publicado en 2016

The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials

artículo científico publicado en 2016

The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials

artículo científico publicado en 2016

The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer

artículo científico publicado en 2017

The coexistence of second and third malignancies in adult-onset cancer patients

artículo científico publicado en 2014

The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence

scientific article published on 13 September 2020

The development of hypertension in metastatic colorectal cancer patients treated with aflibercept: the role of systolic and diastolic blood pressure before starting treatment.

artículo científico publicado en 2016

The effect of palliative care on the assistance of terminally ill cancer patients

scientific article published on 08 June 2013

The exposure to perfluoroalkyl substances (PFAS) and the development of cancer

scientific article published on 01 July 2019

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal

artículo científico publicado en 2020

The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.

artículo científico publicado en 2012

The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?

artículo científico publicado en 2013

The outcome of targeted therapies in patients with poor prognosis metastatic renal cell carcinoma

scientific article published on 01 July 2014

The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agents.

artículo científico publicado en 2016

The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials

artículo científico publicado en 2014

The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs

artículo científico publicado en 2020

The role of palliative surgery in the management of advanced pancreatic cancer in patients with biliary and duodenal obstruction

artículo científico publicado en 2016

Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".

artículo científico publicado en 2015

To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?

scientific article published on 14 September 2020

Trends in survival for patients with metastatic breast cancer: is survival improving?

artículo científico publicado en 2015

Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda